Gatifloxacin-Induced Hyperglycemia

Orlander, Jay D.; Serrao, Richard

doi:10.1097/01.idc.0000130884.04988.d5

Cited by 5 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports of hyperglycemia in elderly patients (age ≥ 65 years old) who received gatifloxacin therapy with and without diabetes diagnoses have been reported in the literature. 1,[3][4][5]7,8,11 Our case report findings are in agreement with the previous literature reports of elderly patients potentially being more at risk for hyperglycemia associated with gatifloxacin therapy. In the Park-Wyllie et al study, patients were elderly, 66 years of age or older, and were treated for a lower-respiratory tract infection.…”

Section: Elderly Patientssupporting

confidence: 92%

“…Two of the 13 previous patients in case reports had a diagnosis of diabetes. 5,8 Our cases are more similar to the clinical trials that both reported more than 60% of patients having diabetes. In our cases, 1 patient was diagnosed with type 2 diabetes after exposure to gatifloxacin therapy.…”

Section: Association With Diabetessupporting

confidence: 80%

“…Glucose dysglycemias (both hyper-and hypoglycemia) had been associated with gatifloxacin use. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] In pre-(n = 16) and postmarketing (n = 70) studies completed by the manufacturer, a mean increase in fasting blood glucose value of 40 mg/dL was reported. 17 However, this change was not found to be statistically significant (no statistical data reported).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Gatifloxacin-Induced Hyperglycemia: A Review of 4 Cases and the Literature

Edwards

Hall

Ceja

2007

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Gatifloxacin, a broad-spectrum fluoroquinolone, has recently been voluntarily withdrawn by Bristol-Myers Squibb from the market secondary to dysglycemic events associated with this agent. Risk factors for this adverse event include diabetes and those who are elderly (65 years of age or older), have renal insufficiency, or take glucose altering medications. The mechanism for this adverse reaction is not fully understood. However, it is theorized that there is an association between accumulation of gatifloxacin (particularly in elderly patients or those with renal insufficiency) and dysglycemic events with gatifloxacin. A review of the literature found 13 reported cases of hyperglycemia induced by gatifloxacin and 2 clinical trials evaluating gatifloxacin's association with hyperglycemia. Similarly to other reported cases, the authors' 4 outpatients were initiated on gatifloxacin therapy and subsequently had developed hyperglycemia during gatifloxacin therapy. Prior to the multiple observations of dysglycemias associated with gatifloxacin, this medication was widely used and thought to have an excellent safety profile. Hence, clinicians should be vigilant and exercise caution with newly approved medications.

show abstract

Section: Elderly Patientssupporting

confidence: 92%

Section: Association With Diabetessupporting

confidence: 80%

mentioning

confidence: 99%

See 1 more Smart Citation

Gatifloxacin-Induced Hyperglycemia: A Review of 4 Cases and the Literature

Edwards

Hall

Ceja

2007

Journal of Pharmacy Practice

View full text Add to dashboard Cite

show abstract

“…Patients with hepatic impairment may be more susceptible to this adverse reaction and should be closely monitored [57]. These episodes occur typically after 3-10 days of receiving gatifloxacin therapy and persist for up to 28 days [58].…”

Section: Fluoroquinolonesmentioning

confidence: 99%

Safety of Newer Parenteral Antibiotics

Stein

2005

CLIN INFECT DIS

View full text Add to dashboard Cite

Several parenteral antimicrobials have been introduced into clinical practice over the course of the last decade. Some of these agents (e.g., linezolid, daptomycin, and tigecycline) are prototypes of new classes of compounds. In comparative clinical trials, these newer anti-infectives have been shown to be safe and to have low rates of discontinuation by patients. However, long-term use has revealed unique toxicities associated with the use of some of these drugs. The adverse events and potential drug interactions associated with the use of these antibiotics are variable and require familiarity with the safety profile of each drug. It is especially important that clinicians be able to recognize serious adverse events associated with the use of specific drugs, because most of the adverse events can be readily reversed by cessation of therapy.

show abstract

“…However, gatifloxacin-which had been used in the treatment of a variety of infections, including those involving the skin and the respiratory and genitourinary tracts [1,2]-was withdrawn from the market because of concerns about severe glucose disturbances. Although hypoglycemia and hyperglycemia were reported only rarely during clinical trials with gatifloxacin, severe dysglycemic events, typically in elderly patients and in patients with diabetes, were re-ported during the postmarketing period [3] and published in the medical literature [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21].…”

mentioning

confidence: 99%